Replagal 1 mg (Agalsidase Alfa SOLUTION) 1 MG

Replagal 1 mg is an intravenous solution containing agalsidase alfa, used for enzyme replacement therapy. This medication is designed to address specific metabolic conditions. Learn more about its uses and effects.

Strength

1 MG

Manufacturer / TM Owner

TAKEDA CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Replagal 1 mg is primarily used for enzyme replacement therapy. It is indicated for patients with certain metabolic disorders that require the administration of agalsidase alfa. This solution is administered intravenously to help manage symptoms associated with these conditions. Patients should consult their healthcare provider to determine if Replagal 1 mg is suitable for their specific needs.

Side Effects

Common effects of Replagal 1 mg may include infusion-related reactions such as chills, fever, and headache. Some patients may also experience fatigue or nausea. These effects are generally mild to moderate and may vary from person to person. Always discuss any concerns with a healthcare professional.

Precautions & Warnings

Replagal 1 mg should be handled with care and administered under the supervision of a healthcare provider. It is important to follow the prescribed dosage and administration instructions. Patients with a history of allergic reactions to agalsidase alfa or any of its components should inform their healthcare provider before use.

Avoid Interactions

Replagal 1 mg may interact with other medications, including those that affect the immune system or blood pressure. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Always consult a healthcare professional for personalized advice.

Frequently Asked Questions

Replagal 1 mg is used for enzyme replacement therapy in patients with specific metabolic disorders.

Replagal 1 mg is administered intravenously by a healthcare provider.

Common effects may include infusion-related reactions such as chills, fever, and headache.

Replagal 1 mg may interact with other medications, so it is important to consult a healthcare provider.

Patients with a history of allergic reactions to agalsidase alfa or any of its components should avoid using Replagal 1 mg.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.